Biofrontera Inc. (BFRI) Stock Analysis & Investment Frameworks
Biofrontera Inc. (BFRI) stock analysis on Invetso. Review Biofrontera Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Biofrontera Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: US
Biofrontera Inc. Key Financial Metrics
- Market Cap: $11.88M
- Revenue: $41.70M
- ROE: -127.78%
- ROIC: -31.18%
- Dividend Yield: N/A
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc. Investment Frameworks
Invetso analyzes Biofrontera Inc. (BFRI) across the following frameworks:
- Biofrontera Inc. 10Y Growth Potential
- Biofrontera Inc. Scenario Analysis
- Biofrontera Inc. Risks & Opportunities
- Biofrontera Inc. Economic Moat
- Biofrontera Inc. Business Model
- Biofrontera Inc. Management
- Biofrontera Inc. SWOT Analysis
- Biofrontera Inc. Porter's 5 Forces
- Biofrontera Inc. PESTLE Analysis
- Biofrontera Inc. ESG Analysis